Essential thrombocytosis

For patient information, click here

Essential thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Essential thrombocytosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Essential thrombocytosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Essential thrombocytosis
CDC on Essential thrombocytosis
Essential thrombocytosis in the news
Blogs on Essential thrombocytosis
Directions to Hospitals Treating Essential thrombocytosis
Risk calculators and risk factors for Essential thrombocytosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Diagnosis

History & Symptoms | Physical Examination | Staging | Lab Tests | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies | Diagnostic criteria

Treatment

Medical Therapy | Special care related to pregnancy | Surgery | Primary Prevention | Secondary Prevention

Resources

• Cancerbackup Essential Thrombocytosis page
• CMPD Education Foundation
• MPD Foundation and Research Alliance - Register for a free newsletter
• Overview of Agrylin, the tradename for anagrelide hydrochloride

Template:WikiDoc Sources